Felix Feng: “When a symposium is named after you, you can pretty much just wax poetic up on stage.”

Keynote address at The Feng Symposium in May 2024

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

On May 18, 2024, Felix Feng, a leader in genitourinary cancer research, gave the keynote address at the inaugural symposium that bears his name. 

Feng died Dec. 10, 2024. He was 48. He is remembered by colleagues at UCSF Helen Diller Family Comprehensive Cancer Center and NRG Oncology in two obituaries in this issue.

“When a symposium is named after you, you can pretty much just wax poetic up on stage,” Feng said. “I’m gonna do that. And to all my mentees in the audience, I always tell you to give a crisp talk—one or two major take-home messages. I’m gonna break all those rules, okay?”

In his address at The Feng Symposium on Prostate Cancer Revolutions, Feng talks about his career, the people who supported him along the way, his mentors, and his mentees.

“As we reflect on Felix’s life and contributions to the field, we hope this Symposium serves as a tribute to his deep compassion and remarkable career,” says a memorial page on The Feng Symposium website. 

The video of his full remarks is available on the Cancer History Project.


This column features the latest posts to the Cancer History Project by our growing list of contributors

The Cancer History Project is a free, web-based, collaborative resource intended to mark the 50th anniversary of the National Cancer Act and designed to continue in perpetuity. The objective is to assemble a robust collection of historical documents and make them freely available.  

Access to the Cancer History Project is open to the public at CancerHistoryProject.com. You can also follow us on Twitter at @CancerHistProj, or follow our podcast.

Is your institution a contributor to the Cancer History Project? Eligible institutions include cancer centers, advocacy groups, professional societies, pharmaceutical companies, and key organizations in oncology. 

To apply to become a contributor, please contact admin@cancerhistoryproject.com.

YOU MAY BE INTERESTED IN

Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login